Fig. 2: Association of PD-L1 expression by IHC with molecular subtypes of ovarian tumors. | Modern Pathology

Fig. 2: Association of PD-L1 expression by IHC with molecular subtypes of ovarian tumors.

From: Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors

Fig. 2

a–h Representative H&E and corresponding PD-L1 IHC images of ovarian tumors classified as immunoreactive (left) and non-immunoreactive (right), using SP142 PD-L1 antibody clone. Histological subtypes of tumors were serous carcinoma (a, c, e, g), endometrioid carcinoma (b, f), and clear cell carcinoma (d, h). Scatter dot plots of PD-L1 expression using CPS (i) and TPS (j) for tumors characterized as immunoreactive (IMM), differentiated (DIF), mesenchymal (MES), or proliferative (POS) molecular subtypes based on TCGA classifiers. Kruskall–Wallis test H = 27.52, p < 0.0001 (i) and H = 25.04, p < 0.0001 (j). Significant Dunn’s tests in i between IMM vs. DIF (33.39, p = 0.0003) and IMM vs. MES (39.63, p < 0.0001); and in j between IMM vs. DIF (30.52, p = 0.0010) and IMM vs. MES (39.24, p < 0.0001). Short line indicates mean value; error bars indicate one standard deviation; * indicates p < 0.05; ns indicates no significance. k, l Percentage of tumors classified as immunoreactive at different CPS and TPS cutoffs.

Back to article page